164 related articles for article (PubMed ID: 36700785)
1. Viewing RCC with a DNA Methylation Lens ENHANCES Understanding of ICI Resistance.
Zhou M; Kim WY
Clin Cancer Res; 2023 Apr; 29(7):1170-1172. PubMed ID: 36700785
[TBL] [Abstract][Full Text] [Related]
2. An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Lu X; Vano Y; Helleux A; Su X; Lindner V; Davidson G; Mouawad R; Spano JP; Rouprêt M; Elaidi R; Compérat E; Verkarre V; Sun C; Chevreau C; Bennamoun M; Lang H; Tricard T; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Clin Cancer Res; 2023 Apr; 29(7):1279-1291. PubMed ID: 36374555
[TBL] [Abstract][Full Text] [Related]
3. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby RM; Labaki C; Jammihal TR; Xie W; Sun M; Shah V; Saad E; Kane MH; Kashima S; Sadak K; El Zarif T; Poduval D; Motzer RJ; Powles T; Rini BI; Albiges L; Pal SK; McGregor BA; McKay RR; Signoretti S; Van Allen EM; Shukla SA; Choueiri TK; Braun DA
Cancer Cell; 2024 May; 42(5):732-735. PubMed ID: 38579722
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
5. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
6. Integrative clinical and molecular characterization of translocation renal cell carcinoma.
Bakouny Z; Sadagopan A; Ravi P; Metaferia NY; Li J; AbuHammad S; Tang S; Denize T; Garner ER; Gao X; Braun DA; Hirsch L; Steinharter JA; Bouchard G; Walton E; West D; Labaki C; Dudani S; Gan CL; Sethunath V; Carvalho FLF; Imamovic A; Ricker C; Vokes NI; Nyman J; Berchuck JE; Park J; Hirsch MS; Haq R; Mary Lee GS; McGregor BA; Chang SL; Feldman AS; Wu CJ; McDermott DF; Heng DYC; Signoretti S; Van Allen EM; Choueiri TK; Viswanathan SR
Cell Rep; 2022 Jan; 38(1):110190. PubMed ID: 34986355
[TBL] [Abstract][Full Text] [Related]
7. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
[TBL] [Abstract][Full Text] [Related]
9. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Labriola MK; Zhu J; Gupta RT; McCall S; Jackson J; Kong EF; White JR; Cerqueira G; Gerding K; Simmons JK; George D; Zhang T
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221016
[TBL] [Abstract][Full Text] [Related]
10. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
11. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
12. Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues.
Yoo SH; Yun J; Keam B; Hong SP; Ock CY; Koh J; Kim S; Jeon YK; Jung KC; Kim M; Kim TM; Kim DW; Kim JI; Heo DS
Cancer Immunol Immunother; 2021 Jun; 70(6):1755-1769. PubMed ID: 33389015
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
14. A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma.
Patel HV; Srivastava A; Srinivasan R; Singer EA
Curr Opin Oncol; 2021 May; 33(3):212-220. PubMed ID: 33818540
[TBL] [Abstract][Full Text] [Related]
15. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Bakouny Z; Braun DA; Shukla SA; Pan W; Gao X; Hou Y; Flaifel A; Tang S; Bosma-Moody A; He MX; Vokes N; Nyman J; Xie W; Nassar AH; Abou Alaiwi S; Flippot R; Bouchard G; Steinharter JA; Nuzzo PV; Ficial M; Sant'Angelo M; Forman J; Berchuck JE; Dudani S; Bi K; Park J; Camp S; Sticco-Ivins M; Hirsch L; Baca SC; Wind-Rotolo M; Ross-Macdonald P; Sun M; Lee GM; Chang SL; Wei XX; McGregor BA; Harshman LC; Genovese G; Ellis L; Pomerantz M; Hirsch MS; Freedman ML; Atkins MB; Wu CJ; Ho TH; Linehan WM; McDermott DF; Heng DYC; Viswanathan SR; Signoretti S; Van Allen EM; Choueiri TK
Nat Commun; 2021 Feb; 12(1):808. PubMed ID: 33547292
[TBL] [Abstract][Full Text] [Related]
16. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas.
Lu X; Vano YA; Su X; Helleux A; Lindner V; Mouawad R; Spano JP; Rouprêt M; Compérat E; Verkarre V; Sun CM; Bennamoun M; Lang H; Barthelemy P; Cheng W; Xu L; Davidson I; Yan F; Fridman WH; Sautes-Fridman C; Oudard S; Malouf GG
Cell Rep Med; 2023 Nov; 4(11):101287. PubMed ID: 37967556
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.
Sekino Y; Teishima J; Liang G; Hinata N
Int J Urol; 2022 Dec; 29(12):1419-1428. PubMed ID: 36122306
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk.
Kartolo A; Holstead RG; Duran I; Robinson AG; Vera-Badillo FE
Urology; 2021 Nov; 157():8-14. PubMed ID: 34461142
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions.
Rambhia A; Patel RD; Okhawere KE; Korn TG; Badani KK
Urol Oncol; 2021 Oct; 39(10):664-677. PubMed ID: 34312081
[TBL] [Abstract][Full Text] [Related]
20. New insight into immune checkpoint inhibitors in the treatment of advanced renal cell carcinoma.
Wang H; Zhu Z; Zhang Y; Jiang T; Zhang M; Wang Z; Zhang Y; Zhao A; Su B
Sci China Life Sci; 2023 Apr; 66(4):875-878. PubMed ID: 36469217
[No Abstract] [Full Text] [Related]
[Next] [New Search]
